CBD or synthetic cannabidiol has shown signs of terminating bacteria that causes meningitis, legionnaires and gonorrhea disease.
IMB’s Botanix Pharmaceuticals Limited and Centre for Superbug Solutions are merging research efforts to identify a new type of antibiotics that destroys resistant bacteria.
Mark Blaskovich, Centre of Superbug Solutions’ director, asserted that CBD’s chief nonpsychoactive element of marijuana can eradicate a broad scope of bacteria such as Neisseria gonorrhoeae that instigate gonorrhea.
Dr Blaskovich noted that the research findings attest for the first time that CBD can kill variants of Gram-negative bacteria. These disease-causing microorganisms have an additional outer membrane working as an extra defence line against antibiotics.
Gonorrhea is the second highly transmitted sexual infection in Australia and current antibiotics can’t fight it due to the disease’s resistant bacteria.
According to the research, CBD is also very proficient against multiple types of Gram-positive bacteria such as methicillin-tolerant golden staph.
Mark added that cannabidiol was perfect in biofilm breakdown. Biofilms are bacteria’s slimy build-up, such as teeth dental plaque, that protect bacteria against antibiotic treatment
Dr Blaskovich’s group replicated a 14-day patient treatment lab model to determine bacteria’s rate of mutation in trying to outpace CBD’s destruction power.
According to the research report, cannabidiol exhibited low bacteria resistance even after researchers sped up development through increasing the antibiotic’s concentration.
Researchers believe that cannabidiol destroys bacteria through blasting their peripheral cell membranes; however, more research is needed to explain how this cannabis product does that.
The research panel also found out that chemical analogs were effective against bacteria.
According to Vince Ippolito, Botanix’s Executive Chairman and President, the research indicated a strong motivation for the creation of efficient treatments to tackle the surging worldwide threat of bacteria’s antibiotic tolerance.
Mr Ippolito thanked Dr Blaskovich and his group for launching a significant research department.ff